Lung cancer (Amsterdam, Netherlands)HumansProto-Oncogene Proteins p21(ras)Lung NeoplasmsCarcinomaNon-Small-Cell Lung
KRAS G12C-associated immunotherapy benefit in NSCLC is substantially mediated by tobacco-induced tumor mutation burden, not allele-specific effects.
Meng Liu, Jeffrey P Townsend
Published: 202510.1016/j.lungcan.2025.108749
Abstract
BACKGROUND: KRAS G12C mutations in non-small cell lung cancer (NSCLC) have been associated with improved immune-checkpoint inhibition (ICI) outcomes. However, it remains unclear whether this benefit reflects allele-intrinsic biology or shared depende…
Preview only. Read the full abstract at the source